T1	PROC 86 97	tratamiento
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	DISO 115 136	uveítis no infecciosa
T3	PROC 165 246	Estudio aleatorizado, frente a placebo, doble enmascarado de eficacia y seguridad
T4	CHEM 250 261	gevokizumab
#2	AnnotatorNotes T4	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 268 279	tratamiento
#3	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 286 307	uveítis no infecciosa
T7	DISO 339 349	panuveítis
#4	AnnotatorNotes T7	C0030343; Panuveitis; Disease or Syndrome
T8	DISO 372 401	Uveítis no infecciosa crónica
T9	DISO 427 448	Uveítis no infecciosa
T10	DISO 469 479	panuveítis
#5	AnnotatorNotes T10	C0030343; Panuveitis; Disease or Syndrome
T11	PROC 508 519	Diagnóstico
#6	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	DISO 523 544	uveítis no infecciosa
T13	DISO 569 579	panuveítis
#7	AnnotatorNotes T13	C0030343; Panuveitis; Disease or Syndrome
T14	ANAT 595 598	ojo
#8	AnnotatorNotes T14	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T15	DISO 698 705	uveítis
#9	AnnotatorNotes T15	C0042164; Uveitis; Disease or Syndrome
T16	DISO 730 740	panuveítis
#10	AnnotatorNotes T16	C0030343; Panuveitis; Disease or Syndrome
T17	DISO 790 797	Uveítis
#11	AnnotatorNotes T17	C0042164; Uveitis; Disease or Syndrome
T18	DISO 855 874	opacidad del vítreo
T19	ANAT 898 901	ojo
#12	AnnotatorNotes T19	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T20	PROC 905 935	Mejor agudeza visual corregida
#13	AnnotatorNotes T20	C1275680; Corrected visual acuity; Diagnostic Procedure
T21	ANAT 964 967	ojo
#14	AnnotatorNotes T21	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T22	PROC 997 1008	tratamiento
#15	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 1027 1043	corticosteroides
#16	AnnotatorNotes T23	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T24	PROC 1052 1059	terapia
#17	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 1265 1286	método anticonceptivo
#18	AnnotatorNotes T25	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T26	DISO 1332 1350	Uveítis infecciosa
T27	DISO 1353 1372	síndromes mascarada
#19	AnnotatorNotes T27	C1444690; Masquerade syndrome; Disease or Syndrome
T28	DISO 1376 1383	Uveítis
#20	AnnotatorNotes T28	C0042164; Uveitis; Disease or Syndrome
T29	ANAT 1445 1448	ojo
#21	AnnotatorNotes T29	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T30	DISO 1497 1506	cataratas
#22	AnnotatorNotes T30	C0086543; Cataract; Anatomical Abnormality
T31	DISO 1509 1531	opacificación capsular
#23	AnnotatorNotes T31	C1306068; After-cataract; Disease or Syndrome
T32	DISO 1594 1603	sinequias
#24	AnnotatorNotes T32	C0154933; Adhesions of iris; Disease or Syndrome | C0334157; Synechia; Pathologic Function
T33	DISO 1619 1642	Enfermedad tuberculosis
T34	DISO 1670 1702	reacción alérgica o anafiláctica
T35	CHEM 1711 1735	anticuerpos monoclonales
#25	AnnotatorNotes T35	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T36	DISO 1755 1764	neoplasia
#26	AnnotatorNotes T36	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T37	DISO 1806 1827	Enfermedad infecciosa
#27	AnnotatorNotes T37	C0009450; Communicable Diseases; Disease or Syndrome
T38	DISO 1831 1848	Inmunodeficiencia
#28	AnnotatorNotes T38	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome
T39	CHEM 68 79	gevokizumab
#29	AnnotatorNotes T39	C3179523; gevokizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	ANAT 868 874	vítreo
#30	AnnotatorNotes T40	C1278893; Entire vitreous body; Body Part, Organ, or Organ Component
T41	CHEM 1064 1080	inmunosupresores
#31	AnnotatorNotes T41	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T42	PROC 1403 1426	Agudeza visual mejorada
T43	CHEM 1567 1578	midriáticos
#32	AnnotatorNotes T43	C0026964; Mydriatics; Pharmacologic Substance
T44	Date 12 16	2012
T45	LIVB 101 110	pacientes
#33	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T49	Duration 394 401	crónica
#34	AnnotatorNotes T49	C0205191; chronic; Temporal Concept
T52	LIVB 980 989	Pacientes
#35	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	Route 1044 1050	orales
#36	AnnotatorNotes T53	C1527415; Oral Route of Drug administration; Functional Concept
T54	LIVB 1125 1131	Hombre
#37	AnnotatorNotes T54	C0025266; Male population group; Population Group
T55	LIVB 1134 1139	mujer
#38	AnnotatorNotes T55	C0043210; Woman; Population Group
T56	Age 1146 1149	≥18
T57	Age 1153 1174	mayoría de edad legal
T58	LIVB 1200 1236	pacientes con potencial reproductivo
T64	PHYS 1464 1480	visión monocular
#39	AnnotatorNotes T64	C0042797; Monocular Vision; Organ or Tissue Function
T65	Duration 1773 1779	5 años
T66	PHYS 1861 1869	Embarazo
#40	AnnotatorNotes T66	C0032961; Pregnancy; Organism Function
T67	PHYS 1871 1880	lactancia
#41	AnnotatorNotes T67	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T68	Spec_cue 1883 1897	posibilidad de
T70	PHYS 1907 1917	embarazada
#42	AnnotatorNotes T70	C0032961; Pregnancy; Organism Function
A1	Assertion T70 Speculated
A2	Status T22 History_of
A3	Status T23 History_of
A4	Status T24 History_of
A5	Status T41 History_of
A6	Assertion T43 Contraindicated
A7	Status T34 History_of
A8	Status T35 History_of
A9	Status T36 History_of
A10	Status T38 History_of
#43	AnnotatorNotes T3	C0034656; Randomization; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product + C0013072; Double-Blind Method; Research Activity + C0511730; Identify product efficacy and safety issues; Health Care Activity
#44	AnnotatorNotes T18	C0152006; Vitreous opacities; Finding 
#45	AnnotatorNotes T33	C0041296; Tuberculosis; Disease or Syndrome
#46	AnnotatorNotes T34	C1527304; Allergic Reaction; Pathologic Function + C0002792; anaphylaxis; Disease or Syndrome
#47	AnnotatorNotes T42	C1275680; Corrected visual acuity; Diagnostic Procedure
T46	Neg_cue 1449 1451	no
T47	PROC 1452 1461	estudiado
A11	Assertion T47 Negated
#48	AnnotatorNotes T47	C0582103; Medical Examination; Health Care Activity (?)
T48	PROC 968 977	estudiado
#49	AnnotatorNotes T48	C0582103; Medical Examination; Health Care Activity (?)
T50	PHYS 1224 1236	reproductivo
A12	Assertion T50 Speculated
#50	AnnotatorNotes T50	C0232896; Reproductive function; Physiologic Function
T51	Spec_cue 1214 1223	potencial
R1	Speculation Arg1:T51 Arg2:T50	
T59	Quantifier_or_Qualifier 1287 1303	altamente eficaz
R2	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T59	
R3	Negation Arg1:T46 Arg2:T47	
R4	Speculation Arg1:T68 Arg2:T70	
T60	Neg_cue 435 437	no
T61	Quantifier_or_Qualifier 438 448	infecciosa
A13	Assertion T61 Negated
#51	AnnotatorNotes T61	C1550587; infectious - Entity Risk; Qualitative Concept
R5	Negation Arg1:T60 Arg2:T61	
T62	Neg_cue 380 382	no
T63	Quantifier_or_Qualifier 383 393	infecciosa
A14	Assertion T63 Negated
#52	AnnotatorNotes T63	C1550587; infectious - Entity Risk; Qualitative Concept
T69	Quantifier_or_Qualifier 534 544	infecciosa
A15	Assertion T69 Negated
#53	AnnotatorNotes T69	C1550587; infectious - Entity Risk; Qualitative Concept
T71	Neg_cue 531 533	no
R6	Negation Arg1:T71 Arg2:T69	
T72	Neg_cue 294 296	no
T73	Quantifier_or_Qualifier 297 307	infecciosa
A16	Assertion T73 Negated
#54	AnnotatorNotes T73	C1550587; infectious - Entity Risk; Qualitative Concept
T74	Neg_cue 123 125	no
T75	Quantifier_or_Qualifier 126 136	infecciosa
A17	Assertion T75 Negated
#55	AnnotatorNotes T75	C1550587; infectious - Entity Risk; Qualitative Concept
R7	Negation Arg1:T74 Arg2:T75	
R8	Negation Arg1:T72 Arg2:T73	
R9	Used_for Arg1:T39 Arg2:T1	
R10	Experiences Arg1:T45 Arg2:T39	
R11	Experiences Arg1:T45 Arg2:T2	
R12	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T75	
T76	Quantifier_or_Qualifier 137 143	activa
#56	AnnotatorNotes T76	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R13	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T76	
T77	Quantifier_or_Qualifier 308 314	activa
#57	AnnotatorNotes T77	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R14	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T77	
R15	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T73	
R16	Negation Arg1:T62 Arg2:T63	
R17	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T63	
R18	Has_Duration_or_Interval Arg1:T8 Arg2:T49	
R19	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T61	
T78	Quantifier_or_Qualifier 449 455	activa
#58	AnnotatorNotes T78	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R20	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T78	
T79	Quantifier_or_Qualifier 798 804	activa
#59	AnnotatorNotes T79	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R21	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T79	
T80	Quantifier_or_Qualifier 1643 1649	activa
#60	AnnotatorNotes T80	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R22	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T80	
T81	Quantifier_or_Qualifier 583 594	al menos un
R23	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T81	
R24	Location_of Arg1:T14 Arg2:T12	
R25	Location_of Arg1:T14 Arg2:T13	
T82	Result_or_Value 878 882	≥ 2+
R26	Location_of Arg1:T40 Arg2:T18	
R27	Has_Result_or_Value Arg1:T18 Arg2:T82	
T83	Quantifier_or_Qualifier 886 897	al menos un
R28	Location_of Arg1:T19 Arg2:T18	
R29	Location_of Arg1:T19 Arg2:T17	
R30	Overlap Arg1:T17 Arg2:T18	
R31	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T83	
T84	Result_or_Value 939 957	al menos 10 letras
R32	Location_of Arg1:T21 Arg2:T20	
R33	Has_Result_or_Value Arg1:T20 Arg2:T84	
R34	Location_of Arg1:T21 Arg2:T48	
R35	Used_for Arg1:T4 Arg2:T5	
T85	Quantifier_or_Qualifier 315 325	intermedia
#61	AnnotatorNotes T85	C0205103; Intermediate; Spatial Concept
R36	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T85	
T86	Quantifier_or_Qualifier 545 555	intermedia
#62	AnnotatorNotes T86	C0205103; Intermediate; Spatial Concept
R37	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T86	
T87	Quantifier_or_Qualifier 706 716	intermedia
#63	AnnotatorNotes T87	C0205103; Intermediate; Spatial Concept
R38	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T87	
T88	Quantifier_or_Qualifier 557 566	posterior
#64	AnnotatorNotes T88	C0205095; Dorsal; Spatial Concept (?)
R39	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T88	
T89	Quantifier_or_Qualifier 718 727	posterior
#65	AnnotatorNotes T89	C0205095; Dorsal; Spatial Concept (?)
R40	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T89	
T90	Quantifier_or_Qualifier 327 336	posterior
#66	AnnotatorNotes T90	C0205095; Dorsal; Spatial Concept (?)
R41	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T90	
T91	Quantifier_or_Qualifier 457 466	posterior
#67	AnnotatorNotes T91	C0205095; Dorsal; Spatial Concept (?)
R42	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T91	
T92	CONC 759 775	historia clínica
#68	AnnotatorNotes T92	C5204342; Clinical History; Intellectual Product
R43	Location_of Arg1:T14 Arg2:T15	
R44	Location_of Arg1:T14 Arg2:T16	
R45	Experiences Arg1:T52 Arg2:T22	
R46	Has_Route_or_Mode Arg1:T23 Arg2:T53	
R47	Used_for Arg1:T41 Arg2:T24	
R48	Used_for Arg1:T23 Arg2:T22	
R49	Experiences Arg1:T52 Arg2:T24	
R50	Combined_with Arg1:T22 Arg2:T24	
T93	Quantifier_or_Qualifier 1016 1023	estable
#69	AnnotatorNotes T93	C0205360; Stable status; Qualitative Concept
R51	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T93	
A18	Status T93 History_of
R52	Has_Age Arg1:T54 Arg2:T56	
R53	Has_Age Arg1:T54 Arg2:T57	
R54	Has_Age Arg1:T55 Arg2:T56	
R55	Has_Age Arg1:T55 Arg2:T57	
T94	PROC 1182 1191	selección
#70	AnnotatorNotes T94	C0242802; Patient Selection; Research Activity
R56	Overlap Arg1:T94 Arg2:T56	
R57	Overlap Arg1:T94 Arg2:T57	
R58	Experiences Arg1:T58 Arg2:T50	
R59	Experiences Arg1:T58 Arg2:T25	
T95	Observation 1241 1249	voluntad
#71	AnnotatorNotes T95	C0600109; Willing; Finding
R60	Overlap Arg1:T95 Arg2:T25	
T96	Quantifier_or_Qualifier 1384 1392	anterior
#72	AnnotatorNotes T96	C0205094; Anterior; Spatial Concept
R61	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T96	
T97	Quantifier_or_Qualifier 1393 1400	aislada
#73	AnnotatorNotes T97	C0205409; Isolated; Functional Concept
R62	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T97	
T98	Result_or_Value 1427 1438	< 35 letras
R63	Has_Result_or_Value Arg1:T42 Arg2:T98	
R64	Location_of Arg1:T29 Arg2:T42	
R65	Location_of Arg1:T29 Arg2:T47	
T99	Quantifier_or_Qualifier 1532 1537	grave
#74	AnnotatorNotes T99	C1547227; Severe - Severity of Illness Code; Intellectual Product
R66	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T99	
T100	Quantifier_or_Qualifier 1604 1615	posteriores
#75	AnnotatorNotes T100	C0205095; Dorsal; Spatial Concept (?)
R67	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T100	
R68	Causes Arg1:T35 Arg2:T34	
T101	Quantifier_or_Qualifier 1703 1708	grave
#76	AnnotatorNotes T101	C1547227; Severe - Severity of Illness Code; Intellectual Product
R69	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T101	
A19	Status T101 History_of
R70	Overlap Arg1:T36 Arg2:T65	
T102	PROC 1793 1802	selección
#77	AnnotatorNotes T102	C0242802; Patient Selection; Research Activity
R71	Before Arg1:T36 Arg2:T102	
T103	PROC 1929 1936	estudio
#78	AnnotatorNotes T103	C0008976; Clinical Trials; Research Activity
R72	Overlap Arg1:T70 Arg2:T103	
R73	Overlap Arg1:T66 Arg2:T103	
R74	Overlap Arg1:T67 Arg2:T103	
#79	AnnotatorNotes T26	C1444604; Infective uveitis; Disease or Syndrome
A20	Experiencer T45 Patient
A21	Experiencer T52 Patient
A22	Experiencer T55 Patient
A23	Experiencer T54 Patient
A24	Experiencer T58 Patient
